This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Havlir, D. V. Articles by Wong, J. K. Search for Related Content PubMed PubMed Citation Articles by Havlir, D. V. Articles by Wong, J. K.

Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years

Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California 94110,¹ Department of Medicine,² Department of Physics, University of California,³ Department of Medicine, Veterans Administration Health Care System, San Diego, California 92093,⁵ Department of Immunology,⁴ Department of Virology, University of Milan, Milan 20157, Italy⁶

Received 2 May 2003/ Accepted 29 July 2003

To provide insight into the dynamics and source of residual viremia in human immunodeficiency virus (HIV) patients successfully treated with antiretroviral therapy, 14 intensely monitored patients treated with indinavir and efavirenz sustaining HIV RNA at <50 copies/ml for >5 years were studied. Abacavir was added to the regimen of eight patients at year 5. After the first 9 months of therapy, HIV RNA levels had reached a plateau ("residual viremia") that persisted for over 5 years. Levels of residual viremia differed among patients and ranged from 3.2 to 23 HIV RNA copies/ml. Baseline HIV DNA was the only significant pretreatment predictor of residual viremia in regression models including baseline HIV RNA, CD4 count, and patient age. In the four of five patients with detectable viremia who added abacavir to their regimen after 5 years, HIV RNA levels declined rapidly. The estimated half-life of infected cells was 6.7 days. Decrease in activated memory cells and a reduction in gamma interferon production to HIV Gag and p24 antigen in ELISpot assays were observed, consistent with a decrease in HIV replication. Thus, in patients treated with efavirenz plus indinavir, levels of residual viremia were established by 9 months, were predicted by baseline proviral DNA, and remained constant for 5 years. Even after years of highly suppressive therapy, HIV RNA levels declined rapidly after the addition of abacavir, suggesting that productive infection contributes to residual ongoing viremia and can be inhibited with therapy intensification.

This article has been cited by other articles:

• Pasternak, A. O., Adema, K. W., Bakker, M., Jurriaans, S., Berkhout, B., Cornelissen, M., Lukashov, V. V. (2008). Highly Sensitive Methods Based on Seminested Real-Time Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 Unspliced and Multiply Spliced RNA and Proviral DNA. J. Clin. Microbiol. 46: 2206-2211 [Abstract] [Full Text]  
• Emu, B., Sinclair, E., Hatano, H., Ferre, A., Shacklett, B., Martin, J. N., McCune, J. M., Deeks, S. G. (2008). HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus Control. J. Virol. 82: 5398-5407 [Abstract] [Full Text]  
• Bailey, J. R., Sedaghat, A. R., Kieffer, T., Brennan, T., Lee, P. K., Wind-Rotolo, M., Haggerty, C. M., Kamireddi, A. R., Liu, Y., Lee, J., Persaud, D., Gallant, J. E., Cofrancesco, J. Jr., Quinn, T. C., Wilke, C. O., Ray, S. C., Siliciano, J. D., Nettles, R. E., Siliciano, R. F. (2006). Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells.. J. Virol. 80: 6441-6457 [Abstract] [Full Text]  
• Gondois-Rey, F., Biancotto, A., Fernandez, M. A., Bettendroffer, L., Blazkova, J., Trejbalova, K., Pion, M., Hirsch, I. (2006). R5 Variants of Human Immunodeficiency Virus Type 1 Preferentially Infect CD62L- CD4+ T Cells and Are Potentially Resistant to Nucleoside Reverse Transcriptase Inhibitors. J. Virol. 80: 854-865 [Abstract] [Full Text]  
• Sharkey, M., Triques, K., Kuritzkes, D. R., Stevenson, M. (2005). In Vivo Evidence for Instability of Episomal Human Immunodeficiency Virus Type 1 cDNA. J. Virol. 79: 5203-5210 [Abstract] [Full Text]  
• Nettles, R. E., Kieffer, T. L., Kwon, P., Monie, D., Han, Y., Parsons, T., Cofrancesco, J. Jr, Gallant, J. E., Quinn, T. C., Jackson, B., Flexner, C., Carson, K., Ray, S., Persaud, D., Siliciano, R. F. (2005). Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART. JAMA 293: 817-829 [Abstract] [Full Text]